Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09NCU
|
|||
| Former ID |
DNCL002700
|
|||
| Drug Name |
GS-6624
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Company |
Gilead Sciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lysyl oxidase homolog 2 (LOXL2) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01769196) A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 681814). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.